

Fernando Cabanillas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2028711/publications.pdf>

Version: 2024-02-01

189
papers

12,412
citations

38660

50
h-index

25716

108
g-index

191
all docs

191
docs citations

191
times ranked

7978
citing authors

#	ARTICLE	IF	CITATIONS
1	Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas. <i>Journal of Clinical Oncology</i> , 1999, 17, 1244-1244.	0.8	3,209
2	Randomized Controlled Trial of Yttrium-90 ⁹⁰ -Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2002, 20, 2453-2463.	0.8	1,069
3	Phase II Study of Proteasome Inhibitor Bortezomib in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 667-675.	0.8	517
4	Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. <i>Cancer</i> , 2006, 106, 1569-1580.	2.0	503
5	Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. <i>Lancet Oncology</i> , The, 2012, 13, 716-723.	5.1	274
6	Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. <i>Cancer</i> , 2003, 97, 586-591.	2.0	232
7	Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. <i>Blood</i> , 2004, 104, 1624-1630.	0.6	231
8	Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R ² MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. <i>British Journal of Haematology</i> , 2010, 150, 200-208.	1.2	213
9	Improvement of Overall and Failure-Free Survival in Stage IV Follicular Lymphoma: 25 Years of Treatment Experience at The University of Texas M.D. Anderson Cancer Center. <i>Journal of Clinical Oncology</i> , 2006, 24, 1582-1589.	0.8	192
10	Long-term results with radiotherapy for stage I-II follicular lymphomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 51, 1219-1227.	0.4	156
11	The Clinical Significance of Molecular Response in Indolent Follicular Lymphomas. <i>Blood</i> , 1998, 91, 2955-2960.	0.6	145
12	Lymphoma of the nasal cavity and paranasal sinuses. <i>Cancer</i> , 1997, 80, 477-488.	2.0	131
13	In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. <i>Mayo Clinic Proceedings</i> , 2015, 90, 996-1000.	1.4	128
14	Radiotherapy during pregnancy for clinical stages IA-IIA Hodgkin's disease. <i>International Journal of Radiation Oncology Biology Physics</i> , 1992, 23, 407-412.	0.4	126
15	Long-Term Follow-Up of a Prospective Study of Combined Modality Therapy for Stage I-II Indolent Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2003, 21, 2115-2122.	0.8	122
16	Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. <i>British Journal of Haematology</i> , 1997, 99, 618-624.	1.2	120
17	Correlation of Bcl-2 Rearrangement With Clinical Characteristics and Outcome in Indolent Follicular Lymphoma. <i>Blood</i> , 1999, 93, 3081-3087.	0.6	118
18	Functional expression of receptor activator of nuclear factor κ B in Hodgkin disease cell lines. <i>Blood</i> , 2001, 98, 2784-2790.	0.6	117

#	ARTICLE	IF	CITATIONS
19	Novel 5' Exonuclease-Based Real-Time PCR Assay for the Detection of t(14;18)(q32;q21) in Patients with Follicular Lymphoma. <i>American Journal of Pathology</i> , 1998, 153, 63-68.	1.9	114
20	Primary Ovarian Non-Hodgkin's Lymphoma: Outcome after Treatment with Combination Chemotherapy. <i>Gynecologic Oncology</i> , 1997, 64, 446-450.	0.6	111
21	Management with chemotherapy only of stage I and II malignant lymphoma of aggressive histologic types. <i>Cancer</i> , 1980, 46, 2356-2359.	2.0	106
22	Localized primary malignant lymphoma of bone. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997, 37, 1087-1093.	0.4	97
23	Human interferon alpha in malignant lymphoma and Hodgkin's disease. Results of the american cancer society trial. <i>Cancer</i> , 1985, 56, 1305-1310.	2.0	95
24	Stage III follicular lymphoma: Treatment results for 76 patients. <i>Cancer</i> , 1986, 58, 1596-1602.	2.0	94
25	Differential Expression of BCL-2 Family Proteins in ALK-Positive and ALK-Negative Anaplastic Large Cell Lymphoma of T/Null-Cell Lineage. <i>American Journal of Pathology</i> , 2001, 159, 527-535.	1.9	90
26	Mantle-cell lymphoma. <i>Lancet Oncology</i> , The, 2001, 2, 141-148.	5.1	90
27	BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. <i>Blood</i> , 2002, 100, 3935-3941.	0.6	90
28	Factors Predicting for Response and Survival in Adults With Advanced Non-Hodgkin's Lymphoma. <i>Archives of Internal Medicine</i> , 1978, 138, 413.	4.3	87
29	Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. <i>Cancer</i> , 2006, 106, 120-127.	2.0	85
30	Rituximab plus hyperfractionated cyclophosphamide alternating with methotrexate and doxorubicin in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. <i>British Journal of Haematology</i> , 2016, 172, 80-88.	1.2	82
31	Localized Primary Non-Hodgkin Lymphoma of the Breast. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1998, 21, 376-380.	0.6	77
32	9'-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma. <i>Cancer Chemotherapy and Pharmacology</i> , 1986, 18, 145-52.	1.1	73
33	Refractoriness to chemotherapy and poor survival related to abnormalities of chromosomes 17 and 7 in lymphoma. <i>American Journal of Medicine</i> , 1989, 87, 167-172.	0.6	71
34	Fine-Needle Aspiration Cytology of Peripheral T-Cell Lymphoma: A Cytologic, Immunologic, and Cytometric Study. <i>American Journal of Clinical Pathology</i> , 1989, 91, 120-131.	0.4	71
35	T-Cell-Rich B Large-Cell Lymphoma Simulating Lymphocyte-Rich Hodgkin's Disease. <i>American Journal of Surgical Pathology</i> , 1996, 20, 193-201.	2.1	68
36	Randomized trial of beta-lactam regimens in febrile neutropenic cancer patients. <i>American Journal of Medicine</i> , 1988, 84, 581-589.	0.6	67

#	ARTICLE	IF	CITATIONS
37	European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease. <i>Cancer</i> , 2002, 94, 1731-1738.	2.0	67
38	CD30 ligand is expressed on resting normal and malignant human B lymphocytes. <i>British Journal of Haematology</i> , 1996, 93, 569-571.	1.2	66
39	Untreated Aggressive Mantle Cell Lymphoma: Results with Intensive Chemotherapy without Stem Cell Transplant in Elderly Patients. <i>Leukemia and Lymphoma</i> , 2000, 39, 77-85.	0.6	64
40	Radiotherapy Alone for Lymphocyte-Predominant Hodgkin's Disease. <i>Cancer Journal (Sudbury, Mass)</i> , 2002, 8, 377-383.	1.0	64
41	Accuracy of diagnosis of malignant lymphoma by combining fine-needle aspiration cytomorphology with immunocytochemistry and in selected cases, southern blotting of aspirated cells: A tissue-controlled study of 86 patients. <i>Diagnostic Cytopathology</i> , 1992, 8, 456-464.	0.5	63
42	Sequential chemotherapy and late intensification for malignant lymphomas of aggressive histologic type. <i>American Journal of Medicine</i> , 1983, 74, 382-388.	0.6	61
43	COINCIDENT RENAL CELL CARCINOMA AND NONHODGKIN'S LYMPHOMA: THE M.D. ANDERSON EXPERIENCE AND REVIEW OF THE LITERATURE. <i>Journal of Urology</i> , 1998, 159, 714-717.	0.2	61
44	Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma. <i>Blood</i> , 2002, 100, 4351-4357.	0.6	59
45	Apoptotic Rate in Peripheral T-Cell Lymphomas. <i>American Journal of Clinical Pathology</i> , 2002, 118, 328-334.	0.4	58
46	Hodgkin's Disease Variant of Richter's Syndrome: Experience at a Single Institution. <i>Leukemia and Lymphoma</i> , 1996, 23, 333-337.	0.6	55
47	Chemotherapy as definitive treatment of stage I-II large cell and diffuse mixed lymphomas. <i>Hematological Oncology</i> , 1985, 3, 25-31.	0.8	54
48	The Role of Mitoxantrone in the Treatment of Indolent Lymphomas. <i>Oncologist</i> , 2005, 10, 150-159.	1.9	54
49	Central nervous system prophylaxis with combined intravenous and intrathecal methotrexate in diffuse lymphoma of aggressive histologic type. <i>Cancer</i> , 1986, 57, 971-977.	2.0	52
50	β -Lactam regimens for the febrile neutropenic patient. <i>Cancer</i> , 1990, 65, 9-16.	2.0	51
51	Nodular malignant lymphomas. Factors affecting complete response rate and survival. <i>Cancer</i> , 1979, 44, 1983-1989.	2.0	49
52	LONG-TERM FOLLOW-UP OF PLATINUM-BASED LYMPHOMA SALVAGE REGIMENS. <i>Hematology/Oncology Clinics of North America</i> , 1997, 11, 937-947.	0.9	49
53	Significance of tumor size and radiation dose to local control in Stage III diffuse large cell lymphoma treated with CHOP-Bleo and radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 1995, 31, 3-11.	0.4	48
54	Coexpression of CD40 and CD40 ligand in B-cell lymphoma cells. <i>British Journal of Haematology</i> , 1998, 103, 270-275.	1.2	47

#	ARTICLE	IF	CITATIONS
55	International prognostic index-based outcomes for diffuse large B-cell lymphomas. <i>Cancer</i> , 2002, 94, 3083-3088.	2.0	47
56	Detection of Chromosome 11q13 Breakpoints by Interphase Fluorescence In Situ Hybridization. <i>American Journal of Clinical Pathology</i> , 2000, 114, 248-257.	0.4	46
57	Chromosomal abnormalities in adult non-endemic burkitt's lymphoma and leukemia: 22 new reports and a review of 148 cases from the literature. <i>Hematological Oncology</i> , 2006, 9, 63-78.	0.8	46
58	Protected environment-prophylactic antibiotic program for malignant lymphoma. <i>American Journal of Medicine</i> , 1979, 66, 74-81.	0.6	44
59	Nephrotoxicity of Combined Cephalothin-Gentamicin Regimen. <i>Archives of Internal Medicine</i> , 1975, 135, 850.	4.3	43
60	Elevated Serum Levels of IL-10 are Associated with Inferior Progression-Free Survival in Patients with Hodgkin's Disease Treated with Radiotherapy. <i>Leukemia and Lymphoma</i> , 2004, 45, 2085-2092.	0.6	43
61	Expression of CD40 ligand (CD154) in B and T lymphocytes of Hodgkin disease. <i>Cancer</i> , 2002, 94, 1-5.	2.0	42
62	Marginal zone lymphomas. <i>Cancer</i> , 2010, 116, 4291-4298.	2.0	42
63	High Serum Interleukin-6 Levels Correlate with a Shorter Failure-Free Survival in Indolent Lymphoma. <i>Leukemia and Lymphoma</i> , 1998, 30, 563-571.	0.6	41
64	Surgical debulking is associated with improved survival in stage I-II diffuse large cell lymphoma. <i>Cancer</i> , 1990, 66, 267-272.	2.0	38
65	High dose therapy and autologous marrow transplantation as salvage treatment for patients with diffuse large cell lymphoma. <i>European Journal of Cancer & Clinical Oncology</i> , 1986, 22, 871-877.	0.9	37
66	An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease. <i>Cancer</i> , 2002, 95, 2534-2538.	2.0	37
67	Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis. <i>European Journal of Haematology</i> , 2006, 77, 387-394.	1.1	37
68	Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial. <i>British Journal of Haematology</i> , 1997, 96, 328-332.	1.2	34
69	Epigenetic therapy of lymphoma using histone deacetylase inhibitors. <i>Clinical and Translational Oncology</i> , 2010, 12, 401-409.	1.2	33
70	The outcome of combined-modality treatments for stage I and II primary large B-cell lymphoma of the mediastinum. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 47, 1281-1285.	0.4	32
71	Thalidomide for patients with recurrent lymphoma. <i>Cancer</i> , 2004, 100, 1186-1189.	2.0	31
72	Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma. <i>Cancer</i> , 2008, 113, 2734-2741.	2.0	31

#	ARTICLE	IF	CITATIONS
73	Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum Î²2â€microglobulin level in patients with diffuse large bâ€cell lymphoma: a new prognostic model. British Journal of Haematology, 2016, 175, 290-299.	1.2	31
74	Long-term outcome of treatment for ann arbor Stage 1 Hodgkin's disease: Patterns of failure, late toxicity and second malignancies. International Journal of Radiation Oncology Biology Physics, 1997, 39, 609-616.	0.4	30
75	Apoptotic Induction in Transformed Follicular Lymphoma Cells by Bcl-2 Downregulation. Leukemia and Lymphoma, 1998, 30, 367-380.	0.6	30
76	Analysis of in-field control and late toxicity for adults with early-stage hodgekinâ€™s disease treated with chemotherapy followed by radiotherapy. International Journal of Radiation Oncology Biology Physics, 2003, 55, 36-43.	0.4	30
77	Long term results of a phase 2 study of vincristine sulfate liposome injection (^Marqibo^{Â®}) substituted for nonâ€liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive nonâ€H</sup>odgkin lymphomas. British Journal of Haematology, 2013, 162, 631-638.	1.2	30
78	Longâ€term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated nonâ€Hodgkin lymphoma. British Journal of Haematology, 2017, 178, 250-256.	1.2	30
79	Trimetrexate in Relapsed T-Cell Lymphoma With Skin Involvement. Journal of Clinical Oncology, 2002, 20, 2876-2880.	0.8	29
80	Advances in Diagnosis and Management of Diffuse Large B-cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 783-796.	0.2	29
81	Outcome of Hodgkin's disease in elderly patients. Hematological Oncology, 1995, 13, 19-27.	0.8	28
82	Primary parotid lymphoma: the effect of international prognostic index on outcome. Leukemia and Lymphoma, 1997, 26, 49-56.	0.6	28
83	Second Malignancies After Chemotherapy and Radiotherapy for Hodgkin Disease. American Journal of Clinical Oncology: Cancer Clinical Trials, 2004, 27, 73-80.	0.6	28
84	Primary Non-Hodgkin Lymphoma of the Small Bowel. Radiology, 1999, 211, 183-187.	3.6	27
85	Primary Effusion Lymphoma in an Hiv-Negative Patient with No Serologic Evidence of Kaposi's Sarcoma Virus. Leukemia and Lymphoma, 2001, 41, 185-189.	0.6	27
86	Front-line management of diffuse large B cell lymphoma. Current Opinion in Oncology, 2010, 22, 642-645.	1.1	27
87	A review and interpretation of cytogenetic abnormalities identified in Hodgkin's disease. Hematological Oncology, 1988, 6, 271-274.	0.8	26
88	Primary mediastinal large cell lymphoma. Hematological Oncology, 1994, 12, 175-184.	0.8	26
89	The Expanding Role of Fludarabine in Hematologic Malignancies. Leukemia and Lymphoma, 1994, 14, 11-16.	0.6	26
90	Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma. Cancer, 2001, 91, 2440-2446.	2.0	26

#	ARTICLE	IF	CITATIONS
91	Is there an increased rate of additional malignancies in patients with mantle cell lymphoma?. <i>Annals of Oncology</i> , 2002, 13, 318-322.	0.6	26
92	Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas. <i>Leukemia and Lymphoma</i> , 2012, 53, 50-56.	0.6	26
93	The adjuvant role of two cycles of MOPP and low-dose lung irradiation in stage ia through iib hodgkin's disease: Preliminary results. <i>International Journal of Radiation Oncology Biology Physics</i> , 1988, 14, 683-692.	0.4	25
94	Tumor Necrosis Factor- α and Interferon- β , but not HTLV-I Tax, are Likely Factors in the Epidermotropism of Cutaneous T-Cell Lymphoma via Induction of Interferon-Inducible Protein-10. <i>Leukemia and Lymphoma</i> , 1998, 29, 315-328.	0.6	25
95	Human central nervous system pharmacology of pentamethylmelamine and its metabolites. <i>Journal of Neuro-Oncology</i> , 1983, 1, 357-364.	1.4	24
96	Unbalanced expression of Fas and CD40 in mantle cell lymphoma. <i>British Journal of Haematology</i> , 1998, 103, 217-219.	1.2	24
97	Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy. <i>Cancer</i> , 2003, 98, 1021-1028.	2.0	23
98	Evaluation of Breast Imaging Reporting and Data System Category 3 mammograms and the use of stereotactic vacuum-assisted breast biopsy in a nonacademic community practice. <i>Cancer</i> , 2004, 100, 710-714.	2.0	23
99	Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen. <i>Cancer</i> , 2005, 104, 345-353.	2.0	23
100	Polysomy of chromosome 12 in 60 patients with non-hodgkin's lymphoma assessed by fluorescence in situ hybridization: Differences between follicular and diffuse large cell lymphoma. <i>Genes Chromosomes and Cancer</i> , 1994, 9, 161-167.	1.5	22
101	Interleukin-13 levels in serum from patients with Hodgkin disease and healthy volunteers. <i>Blood</i> , 2001, 98, 2877-2878.	0.6	22
102	Intensive induction chemotherapy of extensive small cell bronchogenic carcinoma in protected environmentâ€”Prophylactic antibiotic units A preliminary report. <i>International Journal of Radiation Oncology Biology Physics</i> , 1980, 6, 1087-1092.	0.4	21
103	Subdiaphragmatic stage I & II Hodgkinâ€™s disease: long-term follow-up and prognostic factors. <i>International Journal of Radiation Oncology Biology Physics</i> , 1998, 41, 1047-1056.	0.4	21
104	Apoptosis and the BCL-2 gene family - patterns of expression and prognostic value in STAGE I and II follicular center lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999, 44, 19-29.	0.4	21
105	Central lymphatic irradiation for stage Iâ€”III follicular lymphoma: report from a single-institutional prospective study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 57, 316-320.	0.4	21
106	Rising Serum Lactate Dehydrogenase Often Caused by Granulocyte-or Granulocyte-Macrophage Colony Stimulating Factor and not Tumor Progression in Patients with Lymphoma or Myeloma. <i>Leukemia and Lymphoma</i> , 1995, 17, 473-477.	0.6	20
107	Hematopoietic Retroviral Gene Marking in Patients with Follicular Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 1999, 32, 279-288.	0.6	20
108	Mucosa-associated lymphoid tissue lymphoma with initial supradiaphragmatic presentation: natural history and patterns of disease progression. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 48, 399-403.	0.4	20

#	ARTICLE	IF	CITATIONS
109	Chromosomal abnormalities in lymphoma and their correlations with nucleic acid flow cytometry. <i>Cancer Genetics and Cytogenetics</i> , 1986, 21, 99-106.	1.0	19
110	Importance of Esophagogastroduodenoscopy in the Evaluation of Non-Gastrointestinal Mucosa-Associated Lymphoid Tissue Lymphoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2003, 9, 321-324.	1.0	19
111	Effects of intensive induction chemotherapy for extensive-disease small cell bronchogenic carcinoma in protected environment-prophylactic antibiotic units. <i>American Journal of Medicine</i> , 1984, 76, 405-412.	0.6	18
112	Risk Classification for Large Cell Lymphoma using Lactate Dehydrogenase, Beta-2 Microglobulin, and Thymidine Kinase. <i>Leukemia and Lymphoma</i> , 1995, 18, 87-92.	0.6	18
113	Ventricular fibrillation following AMSA. Uncomplicated retreatment following correction of hypokalemia. <i>Cancer</i> , 1983, 52, 557-558.	2.0	17
114	Curability of Advanced Indolent or Low-Grade Follicular Lymphomas: Time for a New Paradigm?. <i>Journal of Clinical Oncology</i> , 2013, 31, 14-16.	0.8	17
115	Comparison of lymphangiograms and gallium scans in the non-Hodgkin's lymphomas. <i>Cancer</i> , 1977, 39, 85-88.	2.0	16
116	Analysis of p53 gene deletions in patients with non-Hodgkin's lymphoma by dual-colour fluorescence in situ hybridization. <i>British Journal of Haematology</i> , 1997, 98, 913-921.	1.2	16
117	Mantle irradiation alone for pathologic stage I and II Hodgkin's disease: long-term follow-up and patterns of failure. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 50, 971-977.	0.4	15
118	Non-Hodgkin's Lymphoma: The Old and the New. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S87-S90.	0.2	15
119	Vitamin C and cancer: what can we conclude--1,609 patients and 33 years later?. <i>Puerto Rico Health Sciences Journal</i> , 2010, 29, 215-7.	0.2	15
120	Quantitative Real-Time Polymerase Chain Reaction for Detection of Circulating Cells with T(14;18) in Volunteer Blood Donors and Patients with Follicular Lymphoma. <i>Leukemia and Lymphoma</i> , 2002, 43, 1589-1598.	0.6	14
121	High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study. <i>British Journal of Haematology</i> , 2017, 177, 263-270.	1.2	14
122	Stage III follicular lymphoma: long-term follow-up and patterns of failure. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 57, 748-754.	0.4	13
123	Variations in Chemotherapy and Radiation Therapy in a Large Nationwide and Community-Based Cohort of Elderly Patients With Non-Hodgkin Lymphoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2007, 30, 163-171.	0.6	13
124	Successful Use of Bortezomib-Lenalidomide Combination as Treatment for a Patient With Plasmablastic Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e275-e277.	0.2	13
125	16-Year Experience at M. D. Anderson Cancer Center with Primary Ki-1 (CD30) Antigen Expression and Anaplastic Morphology in Adult Patients with Diffuse Large Cell Lymphoma. <i>Leukemia and Lymphoma</i> , 1995, 20, 97-102.	0.6	12
126	Interferon-Inducible Protein-10 and the Pathogenesis of Cutaneous T-Cell Lymphomas. <i>Leukemia and Lymphoma</i> , 1996, 24, 103-110.	0.6	12

#	ARTICLE	IF	CITATIONS
127	Phase I Study of Fludarabine and Paclitaxel for the Treatment of Low-Grade Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 1997, 26, 77-82.	0.6	12
128	How important is whole brain radiotherapy for treatment of primary CNS lymphoma?. <i>Lancet Oncology</i> , The, 2010, 11, 1011-1012.	5.1	12
129	Phase <sc>II</sc> study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma. <i>British Journal of Haematology</i> , 2014, 166, 920-928.	1.2	12
130	Soluble CD95 in the Serum of Patients with Low and Intermediate Grade Malignant Lymphomas: Absence of Prognostic Correlations. <i>Leukemia and Lymphoma</i> , 1997, 27, 517-521.	0.6	11
131	The significance of molecular response of follicular lymphoma to central lymphatic irradiation as measured by polymerase chain reaction for t(14;18)(q32;q21). <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 49, 727-732.	0.4	11
132	Outcomes Using Doxorubicin-Based Chemotherapy with or without Radiotherapy for Early-Stage Peripheral T-cell Lymphomas. <i>Leukemia and Lymphoma</i> , 2002, 43, 1769-1775.	0.6	11
133	Effective combination chemotherapy of adult malignant histiocytosis (histiocytic medullary) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.6	10
134	Monosomy 21, partial duplication of chromosome 11, and structural abnormality of chromosome 1q21 in a case of lymphoma developing in a transplant recipient: Characteristic abnormalities of secondary lymphoma?. <i>Cancer Genetics and Cytogenetics</i> , 1987, 24, 7-10.	1.0	10
135	Long-term outcome of treatment for ann arbor Stage I Hodgkin's disease: Prognostic factors for survival and freedom from progression. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997, 38, 593-599.	0.4	10
136	Correlation of Bcl-2 Rearrangement With Clinical Characteristics and Outcome in Indolent Follicular Lymphoma. <i>Blood</i> , 1999, 93, 3081-3087.	0.6	10
137	Use of Retroviral Markers to Identify Efficacy of Purging and Origin of Relapse Following Autologous Bone Marrow and Peripheral Blood Cell Transplantation in Indolent B Cell Neoplasms (Follicular) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tj ETQq1 1 0.784314 rgBT /Overlock 10 Anderson Cancer Center. <i>Human Gene Therapy</i> , 1993, 4, 821-834.	1.4	9
138	High incidence of monosomy 18 in lymphoid malignancies that have bone marrow and peripheral blood involvement. <i>Cancer Genetics and Cytogenetics</i> , 1994, 77, 39-44.	1.0	9
139	Simultaneous presentation of hairy cell leukemia and follicular small cleaved cell lymphoma in a patient with previous diagnosis of renal cell carcinoma. <i>Hematological Oncology</i> , 1995, 13, 63-67.	0.8	9
140	Study of the Natural History of Immunoblastic Lymphadenopathy and Atypical Immunoproliferative Disorders. <i>Cancer Investigation</i> , 1983, 1, 293-299.	0.6	8
141	The hematologic malignancies: Leukemia, lymphoma, and myeloma. <i>Cancer</i> , 1984, 54, 2741-2750.	2.0	8
142	Cisplatin-CBV with Autologous Bone Marrow Transplantation for Relapsed Hodgkin's Disease. <i>Leukemia and Lymphoma</i> , 1993, 9, 71-77.	0.6	8
143	Chromosome X numerical abnormalities in patients with Non-Hodgkin's Lymphoma. <i>Cancer Genetics and Cytogenetics</i> , 1995, 82, 23-29.	1.0	8
144	Paclitaxel plus high-dose cyclophosphamide with G-CSF support in patients with relapsed and refractory aggressive non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 1998, 103, 678-683.	1.2	8

#	ARTICLE	IF	CITATIONS
145	Results with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone followed by radiotherapy with or without prechemotherapy surgical debulking for patients with bulky, aggressive lymphoma. <i>Cancer</i> , 2002, 94, 601-605.	2.0	8
146	Establishment and Characterization of a New Mantle Cell Lymphoma Cell Line M-1. <i>Leukemia and Lymphoma</i> , 2004, 45, 1255-1260.	0.6	8
147	Mantle Cell Lymphoma with t(11;22) (q13;q11.2) an indolent clinical variant?. <i>Leukemia and Lymphoma</i> , 2018, 59, 2509-2511.	0.6	8
148	Improvement in complete response rate, duration of response and survival with adriamycin combination chemotherapy for non-Hodgkin lymphoma: A prognostic factor comparison of two regimens. <i>Medical and Pediatric Oncology</i> , 1978, 4, 321-331.	1.0	7
149	Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2006, 47, 1818-1821.	0.6	7
150	Recent advances in the management of mantle cell lymphoma. <i>Current Opinion in Oncology</i> , 2013, 25, 716-721.	1.1	7
151	Indolent Lymphomas That Present With Clinically Aggressive Features: A Subset of Low-Grade Lymphomas With a Behavior Inconsistent With the Histologic Diagnosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 550-557.	0.2	7
152	Rituximab (R) + Hypercvad Alternating with R-Methotrexate/Cytarabine after 9 Years: Continued High Rate of Failure-Free Survival in Untreated Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2008, 112, 833-833.	0.6	7
153	What Constitutes a "Cure" in Lymphoma?. <i>Leukemia and Lymphoma</i> , 1993, 11, 161-163.	0.6	6
154	A prospective randomized study to compare the molecular response rates between central lymphatic irradiation and intensive alternating triple chemotherapy in the treatment of stage I-III follicular lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 188-193.	0.4	6
155	Philadelphia chromosome without breakpoint cluster region rearrangement in a case of Lennert's lymphoma of suppressor phenotype. <i>Hematological Oncology</i> , 1989, 7, 189-194.	0.8	5
156	Lymphomatous Presentation of CD4+/CD8+ HTLV-1-Related Adult T-cell Leukemia/Lymphoma in an Iranian Woman. <i>Leukemia and Lymphoma</i> , 1994, 12, 471-476.	0.6	5
157	Phase II study of paclitaxel in combination with mitoxantrone and ifosfamide/mesna for patients with relapsed or refractory non-Hodgkin's lymphoma after failure to cytarabine/cisplatin combination. <i>Investigational New Drugs</i> , 1999, 17, 187-192.	1.2	5
158	Hematologic recovery after central lymphatic irradiation for patients with stage I-III follicular lymphoma. <i>Cancer</i> , 2001, 92, 1074-1079.	2.0	5
159	Primary cutaneous non-Hodgkin's lymphoma with aggressive histology: inferior outcome is associated with peripheral T-cell type and elevated lactate dehydrogenase, but not extent of cutaneous involvement. <i>Annals of Oncology</i> , 2002, 13, 1290-1299.	0.6	5
160	HLA class II antigen associated invariant chain gene expression in malignant lymphoma. <i>British Journal of Haematology</i> , 1987, 67, 413-417.	1.2	4
161	Rituximab in DLBCL: 6 years on. <i>Lancet Oncology</i> , The, 2011, 12, 984-985.	5.1	4
162	Successful Treatment of a Patient With Epstein-Barr Virus "Positive" B-Cell Lymphoproliferative Disorder Resembling Post-Transplant Lymphoproliferative Disorder Using Single-Agent Rituximab. <i>Journal of Clinical Oncology</i> , 2011, 29, e658-e660.	0.8	4

#	ARTICLE	IF	CITATIONS
163	Human B Cell Lymphomas: <i>In Vitro</i> and <i>In Vivo</i> Studies on Growth Factors and Cell Growth. <i>Leukemia and Lymphoma</i> , 1993, 10, 51-56.	0.6	3
164	Endocrine Characterization of Primary Mediastinal Lymphoma. <i>Leukemia and Lymphoma</i> , 1996, 23, 613-615.	0.6	3
165	Therapeutic concepts in mantle cell lymphoma. <i>European Journal of Haematology</i> , 2010, 85, 371-386.	1.1	3
166	Results of Upfront Therapy for Marginal Zone Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 879-883.	0.2	3
167	Incidence and Risk Factors for Developing Herpes Zoster Among a Cohort of Patients Diagnosed With Lymphoma at a Community Cancer Center. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e153-e158.	0.2	3
168	Evaluation of the MD Anderson tumor score for diffuse large B-cell lymphoma in the rituximab era. <i>European Journal of Haematology</i> , 2020, 104, 400-408.	1.1	3
169	Hodgkin's disease: Correlation of clinical characteristics with probabilities for negative lymphangiogram vs. negative laparotomy findings in patients with Stage I supradiaphragmatic presentations vs. those in patients with Stage II. <i>International Journal of Radiation Oncology Biology Physics</i> , 1998, 40, 377-386.	0.4	2
170	Dose dense CHOP: When more is not always better!. <i>Leukemia and Lymphoma</i> , 2007, 48, 845-846.	0.6	2
171	Pixantrone: a new agent for relapsed aggressive lymphomas. <i>Lancet Oncology</i> , The, 2012, 13, 654-656.	5.1	2
172	Check this checkpoint inhibitor in lymphoma. <i>Blood</i> , 2017, 130, 234-235.	0.6	2
173	The Baseline PET SUV Correlates Better with Clinical Outcome Than the Post-Therapy PET Scan in Previously Untreated Patients with Histologically Aggressive Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2008, 112, 3588-3588.	0.6	2
174	A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas. <i>Investigational New Drugs</i> , 1994, 12, 217-222.	1.2	1
175	Salvage central lymphatic irradiation in follicular lymphomas following failure of chemotherapy: a feasibility study. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999, 45, 1207-1212.	0.4	1
176	Molecular Response of Follicular Lymphoma to Cyclophosphamide, Doxorubicin, Vincristine, Prednisone C(H)OP or COP-Based Therapy as Measured by Polymerase Chain Reaction Evidence of Translocation (14;18)(q32;q21). <i>Cancer Journal (Sudbury, Mass)</i> , 2004, 10, 49-53.	1.0	1
177	Historical Perspective on the Treatment Challenges of Low-Grade Non-Hodgkin's Lymphoma. <i>Seminars in Hematology</i> , 2007, 44, S2-S6.	1.8	1
178	New developments in the field of diffuse large cell lymphoma. <i>Hematology</i> , 2012, 17, s98-s100.	0.7	1
179	Front-line immunochemotherapy for aggressive non-Hodgkin lymphoma using dose-dense rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone plus granulocyte-macrophage colony stimulating factor and pegfilgrastim as support. <i>Leukemia and Lymphoma</i> , 2012, 53, 1929-1933.	0.6	1
180	A New Salvage Regimen for Aggressive Lymphomas Based on Gemcitabine, Rituximab, and Oxaliplatin Followed by Lenalidomide (GROC-Rev). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 776-783.	0.2	1

#	ARTICLE	IF	CITATIONS
181	Managing Indolent Lymphomas in Relapse. Hematology American Society of Hematology Education Program, 2000, 2000, 166-179.	0.9	1
182	Open Editorial Office. Archives of Internal Medicine, 1978, 138, 1174.	4.3	0
183	Benign Fibrous Histiocytoma in Hodgkin's Disease. Cancer Investigation, 1984, 2, 347-350.	0.6	0
184	Frontline Management of Intermediate Grade Lymphomas at M. D. Anderson Hospital. Leukemia and Lymphoma, 1992, 7, 70-71.	0.6	0
185	Reply to I.E. Haines. Journal of Clinical Oncology, 2013, 31, 1798-1798.	0.8	0
186	Managing Indolent Lymphomas in Relapse. Hematology American Society of Hematology Education Program, 2000, 2000, 166-179.	0.9	0
187	T-Cell Rich B-Cell Lymphoma. American Journal of Surgical Pathology, 1997, 21, 499-500.	2.1	0
188	Rectal adenocarcinoma: proposal for a model based on pretreatment prognostic factors. Puerto Rico Health Sciences Journal, 2012, 31, 52-8.	0.2	0
189	Gastric MALT Lymphoma with Biclonal Gammopathy and Bone Marrow Involvement Mimicking Multiple Myeloma. Puerto Rico Health Sciences Journal, 2020, 39, 275-277.	0.2	0